Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Dec 2 2024 | Welcoming November's New HFSA Members HFSA News Membership Read More Nov 26 2024 | New HFSA Consensus Statement Provides Practical Guide for Implementing Palliative Care with Heart Failure Patients HFSA News Press Release Research Statement Read More Nov 25 2024 | Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Industry News In The News Industry Read More Nov 18 2024 | Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months Industry News In The News Industry Read More Nov 16 2024 | New Episode of the Heart Failure Beat Discusses A Year With HFSA: Dr. James Fang on the State of Heart Failure Care HFSA News Podcasts Provider Education Read More Pagination First page « First Previous page ‹ Previous … Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Page 32 Page 33 … Next page Next › Last page Last »
Nov 26 2024 | New HFSA Consensus Statement Provides Practical Guide for Implementing Palliative Care with Heart Failure Patients HFSA News Press Release Research Statement Read More
Nov 25 2024 | Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Industry News In The News Industry Read More
Nov 18 2024 | Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months Industry News In The News Industry Read More
Nov 16 2024 | New Episode of the Heart Failure Beat Discusses A Year With HFSA: Dr. James Fang on the State of Heart Failure Care HFSA News Podcasts Provider Education Read More
